Transgenic analyses have defined two MyoD enhancers in mammals, the core enhancer and distal regulatory region (DRR); these enhancers exhibit complementary activities and together are sufficient to recapitulate MyoD expression in developing and mature skeletal muscle. DRR activity is restricted to differentiated muscle and persists postnatally, suggesting an important role in maintaining MyoD expression in myocytes and muscle fibers. Here, we use targeted mutagenesis in the mouse to define essential functions of the DRR in its normal chromosomal context. Surprisingly, deletion of the DRR resulted in reduced MyoD expression in all myogenic lineages at E10.5, at least 1 day prior to detection of DRR activity in limb buds and branchial arches of transgenic mice. At later embryonic and fetal stages, however, no defect in MyoD expression was observed, indicating that the DRR is dispensable for regulating MyoD during muscle differentiation. Expression analyses in wild-type and Myf-5 mutant embryos also indicate that the DRR is not an obligate target for Myf-5and Pax-3-dependent regulation. In contrast to embryonic and fetal stages, deletion of the DRR resulted in a pronounced reduction in MyoD mRNA levels in adults, showing a functional requirement for DRR activity in mature muscle. These data reveal essential and redundant functions of the DRR and underscore the importance of loss-of-function enhancer analyses for understanding cis transcriptional circuitry. © 2002 Elsevier Science (USA)
INTRODUCTION
In vertebrate embryos, commitment of cells to the skeletal muscle lineage requires either MyoD or Myf-5, two members of the muscle-specific basic helix-loop-helix transcription factor family. In the absence of these muscle regulatory factors (MRFs), myogenesis fails to occur (Rudnicki et al., 1993) , and presumptive myogenic cells are diverted to nonmuscle lineages (Tajbakhsh et al., 1996; Kablar et al., 1999) . During somite development, MyoD and Myf-5 are activated in a precise temporal and spatial pattern in response to signaling molecules produced by the notochord, neural tube, surface ectoderm, and lateral plate mesoderm (reviewed by Borycki and Emerson, 2000) . Although considerable progress has been made in identifying these signaling proteins, which include Sonic hedgehog (Shh), Wnt proteins, and BMPs and their antagonists, little is known of how MyoD and Myf-5 transcription is initiated and maintained in response to these signals.
Previous gain-and loss-of-function experiments have begun to define the hierarchical relationship between MyoD and other transcriptional regulatory factors expressed in somites. For example, MyoD expression is abrogated in the body muscles of mouse embryos mutant for both Myf-5 and the paired box transcription factor, Pax-3, indicating that these factors function upstream of MyoD (Tajbakhsh et al., 1997) . In addition, a number of transcription factors and cofactors, including Pax-3, Six1, Dach2, and Eya2, have been shown to activate MyoD when overexpressed in somite explant cultures (Maroto et al., 1997; Heanue et al., 1999) . It remains to be determined, however, whether any of these factors regulate MyoD through direct transcriptional interactions with MyoD regulatory sequences. Mutations in Myf-5 (Tajbakhsh et al., 1996; Grass et al., 1996; Tajbakhsh et al., 1997) , Pax-3 (Franz et al., 1993; Tajbakhsh et al., 1997; Borycki et al., 1999b) , and Paraxis (Burgess et al., 1996; Wilson-Rawls et al., 1999) , for example, disrupt somite patterning, raising the possibility that effects on MyoD expression are secondary to their roles in somite morphogenesis. Indeed, in Myf-5 and Pax-3 mutant embryos, muscle precursor cells exhibit migratory defects and may not be positioned properly to receive myogenic signals (Tajbakhsh et al., 1996 (Tajbakhsh et al., , 1997 .
As an essential step toward defining the regulatory pathways that govern myogenic determination and MyoD activation, we have used transgenic mouse analysis to characterize mammalian enhancer sequences that control MyoD expression. These studies showed that 24 kb of human MyoD 5Ј flanking sequence is sufficient to recapitulate endogenous MyoD expression in mouse embryos (Chen et al., 2001) , as well as in normal and injured adult skeletal muscles (unpublished observations). Two muscle-specific enhancers with distinct but overlapping specificity have been characterized within MyoD flanking sequence in humans and mice. A highly conserved core enhancer sequence approximately 20 kb upstream of MyoD is sufficient for early MyoD activation in somites, limb buds, and branchial arches Faerman et al., 1995; Kablar et al., 1998) . Linker-scanner mutagenesis of this 258-bp sequence has identified multiple cis elements required for its activity, including an enhancer region specifically required in myotomal lineages that may represent a target for Myf-5-dependent regulation of MyoD (Kucharczuk et al., 1999; unpublished observations) . The core enhancer also exhibits MRF-independent transcriptional activity (Kablar et al., 1999) , likely reflecting a role in initiating MyoD expression in a subpopulation of muscle progenitor cells early in the myogenic program. However, the core enhancer is not sufficient to maintain MyoD expression in differentiated skeletal muscle, being down-regulated in fetal and neonatal muscle and essentially inactive in adult muscle unpublished observations) .
Five kilobases upstream of MyoD is a second enhancer, the distal regulatory region (DRR), which is unrelated in sequence to the core enhancer and exhibits largely complementary activity in transgenic mice (Tapscott et al., 1992; Goldhamer et al., 1995; Asakura et al., 1995; Kablar et al., 1998; Chen et al., 2001) . DRR activity is entirely MRFdependent (Kablar et al., 1999) and is restricted to differentiated skeletal muscle in vivo (Kablar et al., 1997) , which is reflected as a significant delay in DRR-driven transgene expression in several sites of myogenesis relative to the endogenous MyoD gene (Asakura et al., 1995) . Unlike the core enhancer, the DRR remains active in adult muscle, showing a similar expression profile as the endogenous MyoD gene (Hughes et al., 1993) . Collectively, these data indicate that the core enhancer and DRR have distinct activation and maintenance functions, respectively, that collaborate to establish the dynamic pattern of MyoD expression in embryonic and adult skeletal muscle (Chen et al., 2001) .
Although transgenic studies are a powerful means to characterize activities of transcriptional regulatory sequences, transgenesis is inherently limited in its ability to assess required functions of such elements, as restricted sequences are used that are inserted at heterologous genomic loci (reviewed by Fiering et al., 1999) . To circumvent these limitations, we have used targeted mutagenesis in mice to determine the essential functions and regulatory relationships of the MyoD enhancers in their normal chromosomal context. Here, we report the consequences of targeted deletion of the DRR. Replacement of the DRR with the neo-positive selection marker (DRR neo allele) resulted in a dramatic reduction in MyoD expression in all muscle lineages and at all pre-and postnatal stages tested. Removal of the neo cassette by Cre-mediated recombination (DRR loxP allele), however, produced stage-specific defects in MyoD expression. Analysis of E9.75 embryos showed that the DRR is dispensable for the initiation of MyoD expression in branchial arches and somites. Surprisingly, however, MyoD expression was reduced in E10.5 DRR loxP/loxP embryos, revealing an essential DRR function earlier in the myogenic program than expected from previous transgenic work. The DRR is also required to maintain MyoD expression in adult skeletal muscle, as MyoD levels were reduced by approximately 65% in DRR loxP/loxP leg muscles. In contrast, MyoD expression was not affected in differentiating muscle fibers of embryos and fetuses. In addition, in Myf-5 mutant embryos, Pax-3-dependent recovery of MyoD expression (Tajbakhsh et al., 1997) occurred with normal kinetics in the absence of the DRR, showing that the DRR is not an obligate target for Pax-3-dependent MyoD expression. These data reveal essential and redundant DRR functions in developing and mature skeletal muscle.
MATERIALS AND METHODS

Targeted Mutagenesis and Generation of Chimeric Mice
A 1.9-kb ApaI/XhoI genomic fragment (Ϫ5870 to Ϫ4000 relative to the MyoD transcriptional start site) containing the 714-bp DRR (Tapscott et al., 1992) was targeted for deletion by homologous recombination. Approximately 11 kb of 129/SvJ mouse genomic DNA containing the DRR was isolated by screening a gt11 library (Clontech), cloned into pBluescript KSϩ (Stratagene), and mapped by restriction enzyme digests using standard methods. The 1.9-kb fragment was replaced with a PGKneo-positive selection cassette flanked by loxP sites (from ploxPneo-1; kindly provided by Dr. Marisa Bartolomei), cloned in a 3Ј to 5Ј orientation to avoid possible read-through transcription into the MyoD gene. The targeting construct ( Fig. 1 ) has 5Ј and 3Ј homology arms of approximately 5 and 3 kb, respectively, as well as an HSVtk-negative selection cassette adjacent to the 5Ј homology arm.
Approximately 4 ϫ 10 7 GS1 129/SvJ ES cells (Incyte) were electroporated with 40 g of NotI-linearized targeting vector (800 V, 3 F) and plated on a monolayer of mitomycin C (Sigma)-treated, G418-resistant primary embryonic fibroblasts on 0.1% gelatin (Sigma)-coated tissue culture dishes in ES media [15% FBS (Hyclone), 100 units/ml Penicillin (Gibco), 100 g/ml Streptomycin (Gibco), 2 mM L-glutamine (Gibco), 100 M nonessential amino acids (Gibco), 10 mM Hepes (Gibco), 100 M ␤-mercaptoethanol (Sigma), and 10 3 units/ml ESGRO (Calbiochem) in high glucose DMEM (Gibco)]. After 24 h, selection media was added [ES media containing 200 g/ml Geneticin (LTI) and 1 M ganciclovir] and cells were cultured for 8 -12 days. Resistant ES colonies were expanded and targeted clones identified by Southern analysis of XbaI-digested DNA with a radioactive probe to a 1.1-kb XbaI/ EcoRI fragment that lies outside of the 5Ј homology arm ( Fig. 1 ). Targeting was confirmed by Southern analysis of XhoI-digested DNA with a HindIII/StuI 3Ј probe (data not shown). Targeting frequency was approximately 1 in 150 G418/ganciclovir-resistant clones.
To remove the neo cassette, targeted ES clones were electroporated with 25 g of the Cre expression plasmid pBS185 (Sauer and Henderson, 1990 ; kindly provided by Dr. Brian Sauer) and plated at clonal density. Individual colonies were expanded and screened by Southern blotting with flanking probes to test for the loss of the PGKneo gene and to verify the fidelity of the recombined locus. PCR was used to verify lack of integration of the excised neo cassette and the Cre plasmid.
Targeted ES clones, both with (DRR neo ) and without (DRR loxP ) the neo cassette, were injected into C57 blastocysts by the University of Pennsylvania Transgenic and Chimeric Mouse Facility. Chimeric mice were crossed to C57Bl/6J mice, and germline transmission was assessed by Southern analysis of tail DNA.
Mouse Breeding and Embryo Genotyping
For in situ and Northern analyses, heterozygous DRR mutant mice were mated and litters harvested at various stages with noon of the day of plug considered E0.5. Somite number was used for more accurate staging of embryos from E9.75 to E11.5, according to Rugh (1991) . To obtain DRR loxP ;Myf-5 double mutant embryos, DRR loxP/loxP mice were interbred with Myf-5 ϩ/Ϫ mice to generate DRR ϩ/loxP ;Myf-5 ϩ/Ϫ mice, which were subsequently crossed to DRR loxP/loxP mice to generate DRR loxP/loxP ;Myf-5 ϩ/Ϫ mice. Embryos used for analysis were generated by intercrossing DRR ϩ/loxP ;Myf-5 ϩ/Ϫ mice, or by crossing DRR ϩ/loxP ;Myf-5 ϩ/Ϫ and DRR loxP/loxP ;Myf-5 ϩ/Ϫ mice.
DNA was isolated from yolk sacs and genotyping performed by Southern hybridization as described above.
Whole-Mount in Situ Hybridization
E9.75 to E12.5 embryos were fixed in freshly prepared 4% paraformaldehyde in PBS, and processed for in situ hybridization with a digoxigenin-labeled MyoD RNA probe as previously described (Chen et al., 2001) . Embryos within a comparison group were processed simultaneously and developed for identical times to allow direct comparisons of staining intensities. In order to detect small differences in staining intensities, embryos were inspected frequently during the staining process, and occasionally stained in a fourfold dilution of NBT/BCIP and X-phosphate (Roche).
RNA Isolation and Northern Analysis
Tissues were quick-frozen in liquid nitrogen, and total RNA was isolated by either the LiCl-urea method [Auffray and Rougeon, 1980 ; E11.5 embryos, decapitated (to increase the representation of muscle-specific mRNAs) E15.5 embryos, and 7 day neonatal pooled forelimb and hindlimb muscles] or the guanidine isothiocyanate-CsCl method (Chirgwin et al., 1979 ; adult tibialis anterior, gastrocnemius, or pooled hindlimb muscles) using a Polytron homogenizer for tissue dissociations. Total RNA (5-10 g) was electrophoresed on formaldehyde agarose gels, transferred to Gene-Screen nylon membrane (NEN), and hybridized with a 32 P-labeled full-length mouse MyoD cDNA probe (Radprime kit; Gibco) in PerfectHyb Plus (Sigma) by using standard methods. After exposing blots to phosphor screens and scanning with a Storm Scanner 860 (Molecular Dynamics), blots were reprobed with an 800-bp EcoRI fragment from the rat GAPDH cDNA and rescanned. MyoD hybridization signals were quantified by using ImageQuant software (Molecular Dynamics) and normalized to GAPDH. Analyses were performed at least three times at each time point.
Photomicroscopy
Embryo whole-mount images were photographed by using a Hamamatsu C5810 color video camera and Nikon SMZU stereomicroscope under dark-field illumination. Identical light and camera conditions were used to capture images of littermate embryos processed side by side for in situ hybridization. Images were captured and assembled by using Adobe Photoshop and Illustrator, respectively.
RESULTS
Generation of DRR Mutant ES Cells and Chimeric Mice
To define essential functions of the mouse DRR, the minimal genomic element shown to direct muscle-specific expression in transgenic mice was deleted (Asakura et al., 1995) . This 1.9-kb ApaI/XhoI fragment contains the originally defined 714-bp DRR, which directs muscle-specific expression in cell culture (Tapscott et al., 1992) but has not been assayed in vivo. A standard replacement strategy was used whereby a PGKneo cassette was inserted in place of the 1.9-kb DRR fragment ( Fig. 1A) . As cases of long-range transcriptional inhibition by the neo cassette have been well-documented (reviewed by Olson et al., 1996; Fiering et al., 1999) , the neo cassette was flanked by loxP sites to allow its excision by Cre-mediated recombination (Sauer and Henderson, 1988) . A single transcriptionally inert loxP site (Arango et al., 1999) was present at the DRR locus following Cre recombination.
Chimeric mice were generated from DRR-targeted ES cells, and germ line transmission was achieved for both DRR neo and DRR loxP mutations. Mutant lines were maintained by interbreeding to C57Bl/6J mice, and are in a mixed B6, 129 background. Crosses of heterozygous mice generated viable and fertile DRR neo and DRR loxP homozygous null adult offspring at expected Mendelian ratios (data not shown). In contrast, MyoD null mice produced by a heterozygous cross exhibit reduced survival at weaning .
DRR neo Mice Exhibit a Pronounced Decrease in MyoD Expression in All Myogenic Populations
Whole-mount in situ hybridization and Northern analysis revealed a dramatic decrease in MyoD expression in DRR neo embryos and adult muscle. Embryos exhibited a generalized reduction in MyoD expression in all muscle populations and at all developmental stages examined (E10.5-E15.5), although the timing of MyoD expression was not affected (data not shown). Quantitative Northern blots of RNA isolated from E15.5 embryos and neonatal and adult muscle revealed an 80% reduction in MyoD mRNA levels. Induction of MyoD expression in crush-injured muscle also was severely curtailed (data not shown).
Cre-Mediated Excision of the Neo Cassette Restores Near-Normal Levels of MyoD Expression in Embryos
The dramatic effect on MyoD expression of the DRR neo mutation could result from the deletion of the DRR, inhibitory effects of the neo cassette, or both. To distinguish between these possibilities, MyoD expression was analyzed in DRR loxP embryos by northern hybridization (Fig. 2) .
FIG. 1. (A)
Targeting strategy for the mouse DRR. The 1.9-kb ApaI/XhoI fragment, which contains the DRR, was replaced by a floxed PGKneo cassette. The targeting vector (pDRRneotk) contains a 5-kb 5Ј homology arm delineated by the EcoRI and ApaI restriction sites, and a 3-kb 3Ј homology arm delineated by the XhoI and HindIII restriction sites (ApaI and XhoI sites were destroyed during subcloning). The structure of the locus following homologous recombination (DRR neo ) and Cre-mediated excision of the neo cassette (DRR loxP ) are shown. Diagnostic bands generated using the 5Ј probe on XbaI-digested DNA are indicated above the locus diagrams. A 3Ј probe was also used to verify the integrity of the locus following homologous recombination. (B) Representative Southern blot using the 5Ј probe on XbaI-digested DNA. DNA was isolated from offspring of a cross of heterozygous DRR loxP (lanes 1-7) and DRR neo (lanes 8 -14) mice. All genotypic classes were generated at expected Mendelian ratios.
Interestingly, MyoD mRNA levels were similar in wildtype, heterozygous, and homozygous null embryos at E11.5 and E15.5, showing that the severe, constitutive expression defect observed in DRR neo mutants is the result of inhibition by the neo cassette, and not deletion of the DRR. Thus, the DRR is sufficient (Hughes et al., 1993; Asakura et al., 1995; Kablar et al., 1997) but not required to maintain MyoD expression in differentiating embryonic and fetal muscles.
Whole-mount in situ hybridization was performed on DRR loxP embryos to determine whether the DRR is required in a specific myogenic cell population that would not be discernible by Northern analysis. MyoD expression was observed in epaxial and hypaxial myotome subdomains, in limb buds, and in branchial arches (Fig. 3) , showing no lineage-specific defects in MyoD expression. Interestingly, however, a relatively small but consistent decrease in staining intensity was observed in all myogenic populations at E10.5. The decrease in MyoD expression in the limb buds and branchial arches (Figs. 3B and 3F) reveals that the DRR is necessary but not sufficient (Asakura et al., 1995; Chen et al., 2001) for normal MyoD expression in these myogenic populations at this stage. In the mouse, MyoD mRNA is first detected by whole-mount in situ hybridization in the mandibular arch and interlimb somites at E9.75 (Tajbakhsh et al., 1997; Chen et al., 2001) . We compared MyoD expression in wild-type and DRR loxP/loxP embryos at E9.75 to determine whether the initiation of MyoD expression was impaired by deletion of the DRR. No consistent difference in MyoD expression was observed between wild-type and DRR null embryos based on both staining intensity and the craniocaudal extent of somite expression ( Figs. 3A and 3E) , indicating that the earliest induction of MyoD expression is not dependent on the DRR.
MyoD expression in the myotome is thought to be directed by the complementary activities of the core enhancer and DRR; core enhancer transgenes are active in the medial and lateral aspects of the myotome Goldhamer et al., 1995; Kablar et al., 1998) , whereas DRR transgenes are strongly expressed only in the central myotome at E10.5 and E11.5 (Asakura et al., 1995; Kablar et al., 1998; Chen et al., 2001) . Surprisingly, however, the DRR is not required for MyoD expression in the central myotome at these stages (Figs. 3B, 3C, 3F, and 3G) , suggesting that additional cis elements direct expression to this region normally, or can provide this function in the absence of the DRR.
The DRR Is Not Required for Pax-3-Dependent MyoD Expression
Embryos mutant for both Myf-5 and Pax-3 fail to activate MyoD in the body proper, and are essentially devoid of trunk and limb musculature (Tajbakhsh et al., 1997) . In embryos mutant only for Myf-5, MyoD expression in myotomes is delayed by approximately 2 days, eventually recovering through a Pax-3-dependent mechanism (Tajbakhsh et al., 1997) . To determine whether the DRR is essential for Pax-3-dependent MyoD expression, embryos mutant for both Myf-5 and the DRR were analyzed by in situ hybridization. Deletion of the DRR did not affect the timing or the extent of Pax-3-dependent MyoD expression ( Fig. 4) . As expected, MyoD expression in myotomes was delayed in Myf-5 Ϫ/Ϫ (data not shown) and DRR ϩ/loxP ;Myf-5 Ϫ/Ϫ embryos, with recovery beginning in the lateral myotome by E11.5 ( Fig. 4B ; Tajbakhsh et al., 1997) . Similarly, MyoD expression was observed in the lateral myotomal domains of DRR loxP/loxP ;Myf-5 Ϫ/Ϫ embryos at E11.5 (Fig. 4C ). Staining was slightly reduced in DRR loxP/loxP ;Myf-5 Ϫ/Ϫ embryos relative to DRR ϩ/loxP ;Myf-5 Ϫ/Ϫ embryos (Figs. 4B and 4C) , reflecting the minor quantitative effect of the DRR mutation that was more apparent at E10.5 (Fig. 3) . By E12.5, both heterozygous and null DRR loxP embryos exhibited robust MyoD expression comparable to that of Myf-5 ϩ/ϩ embryos (Figs. 4D-FIG. 2 . DRR loxP/loxP embryos exhibit wild-type MyoD mRNA levels at E11.5 and E15.5. Total RNA was isolated from wild-type and DRR mutant E11.5 embryos and decapitated E15.5 fetuses, and consecutively hybridized with MyoD-and GAPDH-specific, 32 P-labeled probes. MyoD hybridization signals were quantified and normalized to GAPDH levels by using a Storm Scanner 860 and ImageQuant software. 4F), although developing trunk musculature was disorganized, as reported previously (Figs. 4E and 4F; Braun et al., 1992) . We conclude that the DRR is not required for Pax-3-dependent MyoD expression in Myf-5 mutant embryos.
The DRR Is Essential for Normal MyoD Expression in Adults
We tested the requirement for DRR function in postnatal muscle by measuring MyoD mRNA levels in neonatal and adult leg muscles. Deletion of the DRR had only a slight effect (average decrease of 15%) on MyoD expression in pooled 7-day neonatal limb muscles ( Figs. 5A and 5B) . In contrast, MyoD mRNA levels were reduced by 65% in the adult tibialis anterior muscle (Figs. 5A and 5B). A similar reduction was observed in the gastrocnemius and pooled hindlimb muscles of 24-week adults (data not shown). The stage-specificity of the DRR loxP phenotype strongly suggests that the pronounced effect on MyoD expression is not a consequence of disrupted chromatin structure or the presence of a loxP sequence at the MyoD locus. These data demonstrate that the DRR is required to maintain normal levels of MyoD expression in adult muscle and indicate that distinct regulatory mechanisms control MyoD expression in embryonic and mature musculature.
DISCUSSION
An inherent limitation of transgenic studies is their inability to elucidate required functions of transcriptional elements in a native chromosomal context, due to the necessarily limited sequences used as transgenes and their integration at heterologous sites in the genome. While reporter gene assays in transgenic mice have shown that the combined activities of the core enhancer and DRR are sufficient to regulate MyoD expression in embryonic and adult skeletal muscle, whether these enhancers serve unique and necessary functions and possible redundant networks governing MyoD transcription had not been explored previously. In the present study, targeted mutagenesis revealed both essential and redundant DRR functions.
Long-Range Disruption of MyoD Expression by the Neo Cassette
Replacement of the DRR with the neo cassette resulted in a dramatic reduction in MyoD expression to approximately 20% of wild-type levels at all embryonic and postnatal stages tested. Comparable inhibition of MyoD expression also was observed when the neo cassette replaced the core enhancer, approximately 20 kb upstream of MyoD (unpublished observations). Because long-range interference of gene expression by positive selection cassettes such as , which is unrelated to the Myf-5 mutant genotype (see Fig. 3 ). MyoD expression in limb buds (red arrows) and branchial arch-derived myogenic cells (arrowheads) of E11.5 embryos was essentially unaffected by the Myf-5 mutation, consistent with previous observations (Tajbakhsh et al., 1997; Kablar et al., 1997) . (D-F) By E12.5, MyoD expression levels were normal in myotomal muscles of Myf-5 mutant embryos both in the presence (E) and absence (F) of a functional DRR allele. Disorganization of trunk musculature in Myf-5 mutant embryos (arrows) is the result of rib defects associated with the Myf-5 m1 allele . neo have been observed in a number of enhancer-and gene-targeting studies (reviewed by Olson et al., 1996; Fiering et al., 1999) , neo was flanked by loxP sequences to allow its removal by Cre-mediated recombination. At most embryonic stages, removal of the neo cassette restored MyoD expression essentially to wild-type levels (see below), demonstrating that insertion of neo, and not deletion of the DRR, was responsible for the constitutive reduction in MyoD mRNA levels.
Genetic studies have shown that MyoD heterozygotes, which express 50% of normal MyoD mRNA levels, can support normal myogenesis in the absence of Myf-5 (Rudnicki et al., 1992 . In contrast, one wild-type Myf-5 allele is not sufficient to support normal myogenesis in a MyoD mutant background, indicating different threshold requirements for these key regulators of myogenesis (Rudnicki et al., 1993) . Preliminary analysis has shown that late gestational DRR neo/neo ;Myf-5 Ϫ/Ϫ fetuses exhibit histologically normal skeletal muscle (unpublished data), suggesting that 20% of normal MyoD mRNA levels are sufficient to support embryonic myogenesis. Additional analysis, including further titration of MyoD levels by combining MyoD knockout and DRR neo alleles, will provide important insights into MyoD dosage requirements for embryonic myogenesis. Kaul et al. (2000) recently developed a viable Myf-5 loxP knockout strain that lacks rib defects characteristic of the original mutation. Thus, MyoD knockout, DRR neo , and DRR loxP alleles will provide an allelic series with which to study genetic interactions between MyoD and Myf-5 in regulating postnatal muscle growth and regeneration (see Seale and Rudnicki, 2000) .
The DRR Is Not Required in Differentiating Embryonic Skeletal Muscle
Based on transgenic studies, a simple prediction was that DRR loxP embryos would exhibit reduced MyoD expression in differentiating muscle, since expression of DRRlacZ transgenes are restricted to differentiating muscle and core enhancer activity is down-regulated as skeletal muscle differentiates and matures (reviewed in Chen et al., 2001) . In the somite, for example, core enhancer activity predominates in the younger myocytes of the medial and lateral myotomal domains, but is down-regulated in older myocytes of the central myotome Kablar et al., 1998; see Ordahl et al., 2000 and Cinnamon et al., 2001 for discussions of myotome formation). In contrast, DRR activity is largely complementary, and is the only known MyoD regulatory element that exhibits robust activity in the central myotome (Asakura et al., 1995; Kablar et al., 1998; Chen et al., 2001) . Deletion of the DRR, however, did not reduce MyoD expression in the central myotome at E10.5 and E11.5 relative to other myogenic populations, nor was expression significantly diminished in differentiating muscle at any embryonic stage tested. These results demonstrate that the DRR is dispensable for MyoD expression in differentiating skeletal muscle, and suggest that redundant transcriptional networks regulate MyoD in embryos. Surprisingly, although DRR transgene activity is not detected in limb buds and branchial arches at E10.5 (Asakura et al., 1995) , DRR loxP/loxP embryos exhibited a consistent decrease in MyoD expression in somites, limb buds, and branchial arches at this stage. Thus, the DRR plays an essential role early in the myogenic program, likely cooperating with the core enhancer and perhaps other elements to confer wild-type expression levels. The DRR does not regulate the initiation of MyoD expression, however, as deletion of the DRR did not affect MyoD expression at E9.75, the stage at which MyoD expression is first detected by in situ hybridization.
The DRR Is Dispensable for Myf-5-and Pax-3-Dependent MyoD Regulation
Myf-5 and Pax-3 function in parallel genetic pathways to regulate MyoD (Tajbakhsh et al., 1997; Kablar et al., 1997; Borycki et al., 1999a) , although their specific roles have not been elucidated. Both Myf-5 (Tajbakhsh et al., 1996) and Pax-3 (Bober et al., 1994; Williams and Ordahl, 1994; Daston et al., 1996; Tremblay et al., 1998) regulate cell migration of myogenic precursors, raising the possibility that their effects on MyoD expression are an indirect consequence of improper positioning of muscle precursor cells relative to myogenic signals (Daston et al., 1996; Tajbakhsh et al., 1996 Tajbakhsh et al., , 1997 . Alternatively, these transcription factors may play a more direct role in MyoD transcriptional control, a notion consistent with Pax-3 overexpression studies (Maroto et al., 1997) , and the fact that MyoD induction by Shh in somite explants is dependent on Myf-5 (Borycki et al., 1999a) . In addition, both the core enhancer and the DRR contain multiple E-boxes (Tapscott et al., 1992; Goldhamer et al., 1995; Chen et al., 2001 ) and a potential binding site for the paired DNA binding domain of Pax factors (Phelan and Loeken, 1998) . That deletion of the DRR did not phenocopy the MyoD expression defect in Myf-5 mutant embryos indicates that the DRR is not an obligate target for Myf-5 regulation of MyoD. Interestingly, deletion of a conserved E-box in the core enhancer results in a pattern of transgene expression that closely resembles endogenous MyoD expression in Myf-5 mutant embryos (Kucharczuk et al., 1999; unpublished observations) suggesting that Myf-5-dependent regulation of MyoD may function through the core enhancer, a possibility being addressed by targeted mutagenesis.
In Myf-5 mutant embryos, MyoD expression in the trunk is entirely dependent on Pax-3 (Tajbakhsh et al., 1997) . The DRR apparently can mediate Pax-3-dependent expression, as a DRR transgene was expressed in the myotomes of Myf-5 mutant embryos (Kablar et al., 1997) . Targeted deletion of the DRR, however, did not affect the timing or extent of Pax-3-dependent MyoD expression, showing that the DRR is not an essential Pax-3 target and that other sequences can also mediate Pax-3-dependent regulation. A likely candidate is the core enhancer, as a core enhancer transgene was also expressed in Myf-5 mutants (Kablar et al., 1998) . In this regard, it will be important to determine how two enhancers of unrelated sequence and distinct activities can function in the Pax-3-dependent transcriptional pathway, and whether Pax-3 directly binds these enhancers or functions by regulating genes involved in cell migration (reviewed by Birchmeier and Brohmann, 2000) or other processes upstream of MyoD expression.
The DRR Is Required to Maintain Normal MyoD Expression Levels in Adult Skeletal Muscle
Deletion of the DRR resulted in a 65% reduction in MyoD expression in the adult tibialis anterior, gastrocnemius, and pooled hindlimb muscles. It is likely that this mutation affects MyoD transcription in muscle fibers themselves, as MyoD is not expressed in quiescent satellite cells (Maley et al., 1994; Smith et al., 1994; Yablonka-Reuveni and Rivera, 1994; Cornelison and Wold, 1997) , and few myoblasts are present in mature skeletal muscle (Snow, 1977) . The present study did not address whether all muscle fiber types were affected similarly by the DRR mutation. In this regard, the endogenous MyoD gene as well as DRR transgenes are expressed at higher levels in fast glycolytic fibers than in slow fibers (Hughes et al., 1993) ; a requirement for the DRR in a subset of fast fiber types could potentially explain a reduction in MyoD mRNA levels of the magnitude observed. Nevertheless, these data demonstrate that maintenance of normal MyoD levels in mature skeletal muscle depends on DRR function, and point to differences in transcriptional pathways or compensatory mechanisms operative in immature and mature muscle. One similarity with regulation of MyoD in embryos, however, is a reliance on multiple regulatory pathways, as deletion of the DRR did not abrogate MyoD expression in adult muscle.
A 1.9-kb DRR-containing fragment was targeted, as this is the minimum sequence that has been tested for DRR activity in transgenic mice (Asakura et al., 1995) . Although the precise DRR sequences required for MyoD expression in adult muscle and early embryos remain to be delineated, we favor the view that the required regulatory information is contained within the originally defined 714-bp DRR (Tapscott et al., 1992) . First, the 714-bp DRR exhibits muscle specificity in cell culture (Tapscott et al., 1992) and contains several motifs for known muscle regulatory factors (Tapscott et al., 1992; Chen et al., 2001) . Second, it shows extended blocks of sequence conservation between humans and mice, whereas other sequences within the 1.9-kb fragment exhibit minimal conservation (Chen et al., 2001) . Third, the 714-bp DRR sequence is subject to chromatin modification by MyoD in cell culture (Gerber et al., 1997) , providing a possible means for maintaining MyoD gene expression by autoregulation (see Thayer et al., 1989) . In this latter regard, it will be interesting to determine whether chromatin modification of the DRR occurs in vivo and whether this modification is MyoD-dependent.
Enhancer Redundancy
Taken together with previous transgenic data, the present results indicate that redundancy is an integral aspect of the transcriptional circuitry regulating MyoD expression. We are currently investigating whether other enhancers exist with DRR-like specificity, or whether the core enhancer, despite its apparently distinct activities, can compensate in the absence of the DRR. Using similar targeting strategies, gene regulation by redundant cis elements has also been documented for ␤-globin (Fiering et al., 1995) , HoxD (Zakany et al., 1997; Beckers and Duboule, 1998) , and the T cell receptor variable region genes (Monroe et al., 1999) , raising the possibility that gene regulation by functionally interchangeable cis motifs is a common theme in development, as suggested by transgenic studies in a variety of species (reviewed by Arnone and Davidson, 1997; Dover, 2000) . Redundancy of regulatory regions such as the DRR could result from the presence of multiple enhancers that can each act as targets for transcription factor mediators of a particular developmental pathway. Alternatively, functionally equivalent but distinct signaling and transcriptional pathways may each activate transcription through a unique DNA target. In this regard, enhancer-targeted mice will be valuable reagents to directly link Shh, Wnt, and other signaling pathways with transcriptional responses that regulate MyoD expression.
